Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled for September 14-16, 2026, in New York City, with the webcast set for September 14 at 9 a.m. EDT. A replay will be available on the Events & Presentations page of Helus Pharma's investor relations website.
This announcement is significant for investors and the mental health community alike. Helus Pharma, formerly known as Cybin Inc., is advancing a pipeline of proprietary NSAs designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder (GAD). These programs address large unmet needs in mental health, where current treatments often have limited efficacy or delayed onset of action.
The participation of CEO Michael Halstead at a major investment conference provides a platform to discuss recent developments, clinical progress, and future milestones. For investors, such presentations offer insights into the company's strategy and the potential of its therapeutic candidates. The webcast allows shareholders and interested parties to hear directly from leadership, fostering transparency and confidence.
Helus Pharma's focus on NSAs represents a novel approach to treating depression and anxiety, aiming for durable improvements by targeting neuroplasticity. The Breakthrough Therapy Designation for HLP003 underscores its potential to offer significant advantages over existing therapies. If successful, these treatments could transform the standard of care for millions suffering from mental health conditions.
The company operates in Canada, the United States, the United Kingdom, and Ireland, and has an extensive research portfolio of investigational NSAs. For more details about Helus Pharma and its pipeline, visit www.helus.com or follow the team on social media platforms. The latest news and updates are available in the company's newsroom at https://ibn.fm/HELP.
InvestorWire, a provider of press release syndication and communications services, disseminated this announcement. The conference participation is an opportunity for Helus Pharma to highlight its progress and engage with the investment community, potentially attracting new partnerships and funding to advance its clinical programs.
As mental health disorders continue to rise globally, innovative treatments like those being developed by Helus Pharma are critical. The company's presence at the H.C. Wainwright conference signals its commitment to advancing its pipeline and bringing new hope to patients. The webcast will offer a closer look at the company's vision and the science behind its NSA platform.
